press releases

home > press releases
Dec 17 Addex Starts a Second Phase IIb Trial of ADX10059 in GERD
Dec 17 Addex Starts a Phase IIb Trial of ADX10059 for Migraine Prevention
Dec 2 Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients
Nov 12 GSK Reports Owning 5% of Addex
Oct 15 Addex Parkinson’s Product Progressing in Early Clinical Trials
Sep 26 GSK Reports Owning 3% of Addex
Sep 10 Better Tolerated Formulation of ADX10059 Reduces Acid Reflux
Aug 7 Disclosure of Shareholdings in Accordance with Stock Market Rules
Aug 5 Disclosure of Shareholdings in Accordance with Stock Market Rules
Jul 28 Addex Pharmaceuticals Reports First Half 2008 Financial Results, Maiden Profit
Jul 28 Laurent Galibert Appointed Head of Inflammation Business Unit
Jul 18 Addex First Half 2008 Financial Results Monday, July 28
Jun 4 Addex Starts Phase I ADX10059 Interaction Study
May 27 Disclosure of Shareholdings in Accordance with Stock Market Rules
Apr 24 Addex Starts ADX10059 Phase I Formulation Selection Study
Apr 18 Addex Appoints Laurent Massuyeau as Head of Business Development
Apr 18 Addex Shareholders Elect Ray Hill to Board of Directors at the 2008 Annual General Meeting
Mar 28 Addex Pharmaceuticals R&D Day on April 24
Mar 26 Mark Epping-Jordan, Chief Scientific Officer, Resigns
Mar 17 Disclosure of Shareholdings in Accordance with Stock Market Rules
Feb 26 Addex Pharmaceuticals 2007 Financial Results
Feb 25 Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
Jan 3 Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
Jan 3 Addex Announces ADX10059 Phase IIa Acute Anxiety Data